Value
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.1 |
| P/S | 9.8 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 6.3 |
| PEG | 5.1 |
| Analyst target | 3.0 |
- ▸Forward P/E: 20.3x
- ▸PEG: 1.48
UNH · Why this verdict
Why UnitedHealth Group (UNH) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Despite being a large healthcare insurer, UNH scores only 4.1 on quality with no competitive moat identified, thin operating margins of 3.2 out of 10, and a net margin score of 1.3 out of 10, suggesting the business generates less earnings quality than its scale might imply. Quality breakdown | Quality score rises above 5.0 within 12 months as margin improvement programs and healthcare segment performance normalize | →Stable |
| CounterFree cash flow conversion at 147% of net income — excellent cash quality — partially offsets the low margin scores and suggests the accounting earnings understate actual cash generation capacity | ||
UnitedHealth has failed the legal news gate, indicating active legal or regulatory news that the scoring engine treats as a hard entry block — a rare gate failure typically reserved for material litigation or investigation risk that has become publicly known. Engine gate (failed) | The legal news gate clears within 12 months as the legal matter resolves without material financial impact, removing the hard entry block | →Stable |
| CounterLarge diversified healthcare companies routinely face legal proceedings, and if the matter is manageable in scale, the legal gate failure may be overstating the risk relative to the long-term business durability | ||
At $411.04, UNH is trading above its resistance-level take-profit of $405.87 with negative asymmetry of -1.15 and negative upside of -10.8%, meaning there is no favorable price entry and the stock has run ahead of near-term analyst targets. Targets | Price corrects below $380, more than 7% below the current $411.04, restoring positive upside to analyst targets and an asymmetry ratio above 1.5 | →Stable |
| CounterStrong momentum of 7.2 with RSI at 78 and rising OBV indicate genuine institutional buying interest; the stock may hold current levels or advance further before a pullback occurs | ||
Risk-based health insurance products represent 80% of UnitedHealth's revenue mix, creating concentration risk where changes in medical cost trends, reimbursement rates, or regulatory medical loss ratio requirements could rapidly erode profitability across the majority of the business. Bear case | Medical cost ratios and regulatory requirements remain within 5% of current levels, preventing margin compression across the risk-based product portfolio over the next 12 months | →Stable |
| CounterThe risk-based business model has been UNH's core for decades and management has consistently adapted to medical cost trends; the concentration reflects deliberate strategic positioning rather than inadvertent risk accumulation | ||
Despite being a large healthcare insurer, UNH scores only 4.1 on quality with no competitive moat identified, thin operating margins of 3.2 out of 10, and a net margin score of 1.3 out of 10, suggesting the business generates less earnings quality than its scale might imply.
→StableQuality breakdown
- Expectation
- Quality score rises above 5.0 within 12 months as margin improvement programs and healthcare segment performance normalize
CounterFree cash flow conversion at 147% of net income — excellent cash quality — partially offsets the low margin scores and suggests the accounting earnings understate actual cash generation capacity
UnitedHealth has failed the legal news gate, indicating active legal or regulatory news that the scoring engine treats as a hard entry block — a rare gate failure typically reserved for material litigation or investigation risk that has become publicly known.
→StableEngine gate (failed)
- Expectation
- The legal news gate clears within 12 months as the legal matter resolves without material financial impact, removing the hard entry block
CounterLarge diversified healthcare companies routinely face legal proceedings, and if the matter is manageable in scale, the legal gate failure may be overstating the risk relative to the long-term business durability
At $411.04, UNH is trading above its resistance-level take-profit of $405.87 with negative asymmetry of -1.15 and negative upside of -10.8%, meaning there is no favorable price entry and the stock has run ahead of near-term analyst targets.
→StableTargets
- Expectation
- Price corrects below $380, more than 7% below the current $411.04, restoring positive upside to analyst targets and an asymmetry ratio above 1.5
CounterStrong momentum of 7.2 with RSI at 78 and rising OBV indicate genuine institutional buying interest; the stock may hold current levels or advance further before a pullback occurs
Risk-based health insurance products represent 80% of UnitedHealth's revenue mix, creating concentration risk where changes in medical cost trends, reimbursement rates, or regulatory medical loss ratio requirements could rapidly erode profitability across the majority of the business.
→StableBear case
- Expectation
- Medical cost ratios and regulatory requirements remain within 5% of current levels, preventing margin compression across the risk-based product portfolio over the next 12 months
CounterThe risk-based business model has been UNH's core for decades and management has consistently adapted to medical cost trends; the concentration reflects deliberate strategic positioning rather than inadvertent risk accumulation
TrendMatrix Research · core thesis
Engine thesis — one sentence
UnitedHealth Group trades at a quality score of only 4.1 out of 10 with no identified competitive moat, is trading at or above analyst target resistance with negative asymmetry, and has an active legal news gate failure — three simultaneous risk factors that collectively prevent a favorable entry at current prices.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.1 |
| ROA | 2.5 |
| Gross margin | 0.0 |
| Op margin | 3.2 |
| Net margin | 1.3 |
| Current ratio | 3.2 |
| FCF quality | 9.9 |
| Moat | 5.0 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 147% FCF/NI
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 7/9
Growth
2.5/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.0 |
| EPS growth | 2.1 |
Momentum
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.3 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.1 |
| Analyst rating | 7.5 |
| Price target | 4.5 |
- ▸LLM news sentiment: +0.42 (n=10)
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider selling — $284,000 (0.000% of mkt cap)
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.5 |
| quality rank | 7.3 |
| growth rank | 1.8 |
- ▸Best-in-class margins
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.9 |
| support resistance | 1.1 |
| 52w position | 9.8 |
Risk (lower is worse)
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.9 |
| days to cover | 8.4 |
| volatility | 6.5 |
| put call | 5.6 |
| implied vol | 5.0 |
| beta | 9.2 |
| debt equity | 6.6 |
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 3.2 |
| dividend safety | 6.0 |
| news activity | 8.0 |
- ▸Earnings in 13 days
- ▸Dividend: 218.0%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:5.1>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-1.4=NEGATIVE
Warning (2)
- MOMENTUM:5.1<5.5 (soft — BUY_NOW allowed but watch)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
-1.45
Upside
-12.9%
Downside
8.9%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 64, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.7 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Risk (lower is worse) at 7.2) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-1.4=NEGATIVE) reinforce the read. Current asymmetry R:R is -1.45 — supplementary context, not the trigger for this path.
The strongest dimensions are Risk (lower is worse) at 7.2, Sentiment at 6.5, and Catalyst at 5.5; the weakest are Growth at 2.5, Technical at 3.9, and Quality at 4.1. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -1.45 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Legal News Gate Active Risk
Trip ifLegal news gate remains active for more than 12 months or a material adverse ruling exceeds $1 billion in financial impact
- P2Below Analyst Target Negative Asymmetry
Trip ifPrice rises above $430, more than 4% above current $411.04, further exceeding resistance without analyst target revision
- P3Quality Below Average No Moat
Trip ifQuality score falls below 3.5 or net margin score drops below 1.0 for 2 consecutive quarters
- P4Product Concentration Risk Based
Trip ifMedical loss ratio rises above 90% or revenue from risk-based products declines by more than 5% year-over-year